Please login to the form below

Life with multiple myeloma - why I'm a lucky man living the dream

Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling from London to the Arc de Triomphe.

Multiple myeloma patient Bob Munro (pictured below) explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling from London to the Arc de Triomphe.

To describe yourself as lucky when you’ve been diagnosed as having a rare incurable bone marrow cancer could easily qualify you for a visit from the men in white coats, but then what’s another couple of white coats when you’ve been surrounded by them for more than seven years?

It certainly wasn’t my first reaction when the consultant treating me for pneumonia told me I had a tumour. “You mean cancer?” I interrupted, sensing that this wasn’t a word he wanted to use. “Yes, it’s in your bone marrow and it’s called myeloma”, which it turns out 97% of people, including me, have never heard of. I’ve had better news.​

As I dabbed away tears, I managed to take on board ‘rare, incurable, treatable, new drugs, great strides’ but the fact that it was in my bones strongly suggested to me that I was in big trouble. Surely once a cancer has migrated to your bones, you were finished? And his coup de grace “oh, and I strongly advise you not to Google it”, meaning you didn’t need to be Sherlock Holmes to know it wasn’t good.

It was no wonder he gave me that earnest but useless piece of advice; 25% of newly diagnosed patients die within the first year and only 46% live for five years. But, and here’s where I start to get lucky, my cup is resolutely half full. Some would say I’m foolishly optimistic.

Google also told me the average age at diagnosis is 69, and less than 35% of patients are under 65. I was 52 and still playing five-a-side football; surely youth and fitness must improve my chances of being in the 46%? It does, so does not having an aggressive strain.

What is multiple myeloma?

Myeloma crowds out the production of red and white blood cells in the bone marrow, leaving sufferers anaemic and with seriously compromised immune systems– hence my raging pneumonia and immediate blood transfusions. It also attacks bones, often resulting in catastrophic collapsed vertebra, and destroys the kidneys. My excessive tiredness –”Stop yawning Dad” – and stubborn infections, suggested I’d had myeloma for a couple of years, but I had neither serious vertebra or kidney damage. This could have been so different if I hadn’t recklessly gone skiing with what felt like flu and developed pneumonia, leading to a diagnosis which could otherwise have been delayed years. Oh yes, that was lucky.

I’m living (cycling) proof of the strides being made in the development of myeloma drugs

Didn’t he say there had been new drugs developed recently and it was treatable? Yes, and 20 years ago there was virtually nothing available. Since my diagnosis there have been an incredible number of new Myeloma treatments, the most for any cancer, so you could say I was lucky… you get the picture. Which is one of the reasons I’m such a, sometimes unfashionably, huge fan of Big Pharma, I literally wouldn’t be alive without it.

My treatment journey

Now, in case you’re thinking this is a rather flippant recollection, coloured by successful treatment to a state of complete remission, think again. The first day’s treatment, a cocktail of 40+ chemotherapy tablets including the notorious, and previously banned thalidomide, left me hospitalised again for three weeks. 
After four months of treatment my response was ‘sub-optimal’ i.e: ‘it didn’t work’. It also left me blind in one eye as the blood thinners I self-injected every day sent blood gushing through my retina. “That was unlucky” said my Ophthalmist. I didn’t see it coming either.

The second treatment also failed to dent the myeloma and left me with permanent numbness in my feet. My consultant then suggested we “smash your myeloma” with two doses of a rather nasty cocktail of six chemotherapy drugs at once. Apart from losing my hair, I felt relatively unscathed, unfortunately so did the myeloma, in fact my biomarkers went up.

The aim had been to lower these biomarkers sufficiently to undergo a stem cell transplant – a huge chemo blast to the bone marrow followed by a transplant of the stem cells drawn from my blood. But with the biomarkers still high, this plan was shelved. So, after 12 months and 4 failed and pretty gruelling treatments, my myeloma was classed as refractory ‘resistant to treatment’ and relapsed – things were looking pretty grim. Was I worried? Would worrying help?

My consultant then prescribed the very latest maintenance therapy, and the results were almost immediate. My biomarkers began falling to manageable levels and the lower toxicity of the drug meant I started to feel more normal again. I resolved to do everything I could to improve my chances of surviving and started walking and improving my diet. During 2013, I recovered some fitness and shed the two stone in weight I had accumulated during treatment. It’s hard to resist chocolate when you might have already had your last beach holiday, but it’s easier when it might help prolong your life.

DOWNLOAD THE FULL ARTICLE HERE

10th January 2020

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world
Our parent company, Fishawack Health has reorganized to deliver agile and innovative solutions for life-sciences companies in the face of rapidly changing markets
Blue Latitude Health
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health